# US 10,441,654 B2 · SMC combination therapy for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,654 B2
- Document ID: US10441654B2
- Status: Granted
- Kind: B2
- Application number: 15/113,634
- Filed: 2015-01-26
- Published: 2017-08-24
- Granted: 2019-10-15
- Earliest claimed: 2014-01-24
- Assignees: Children's Hospital of Eastern Ontario Research Institute Inc.
- Applicants: Children's Hospital of Eastern Ontario Research Institute Inc.
- Inventors: Robert G. Korneluk; Eric C. Lacasse; Shawn T. Beug; Vera A. Tang
- Web page: https://patentgrep.com/patent/US10441654B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/409: having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555)
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 35/761: Adenovirus
- A61K 35/765: Reovirus; Rotavirus
- A61K 35/766: Rhabdovirus, e.g. vesicular stomatitis virus
- A61K 38/21: Interferons {[IFN]}
- A61K 38/212: {IFN-alpha}
- A61K 39/0011: {Cancer antigens}
- A61K 39/205: Rhabdoviridae, e.g. rabies virus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- A61K 2039/55594: {from bacteria}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2760/20134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.

## Claims

### Claim 1

A composition comprising LCL161 or a pharmaceutically acceptable salt thereof and a vesicular stomatitis virus (VSV) Δ51.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

### Claim 3

A kit comprising LCL161 or a pharmaceutically acceptable salt thereof and a VSVΔ51.

### Claim 4 (depends on 3)

The kit of claim 3, wherein the LCL161 and the VSVΔ51 are formulated as separate compositions.

### Claim 5 (depends on 4)

The kit of claim 4, wherein the LCL161 and the VSVΔ51 are formulated as a single composition.

### Claim 6 (depends on 3)

The kit of claim 3, further comprising instructions for administration.